JPRN-UMIN000011679招募中2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer - CCOG1202
Chubu Clinical Oncology Group0 个研究点目标入组 25 人开始时间: 2013年9月8日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Treatment of TS-1 within a week. 2)Patient who had treatment including irinotecan. 3)Uncontrolled infection. 4)Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated 5)Previous history of thoromboembolitic disease,or necessity for antithrombotic drug. 6)Severe lung disease.(Interstitial lung disease or pulmonary fibrosis.) 7)Severe liver disease. 8)Severe renal failure. 9)Previous history of severe drug-induced allergy 10)Intestinal bleeding, ileus, bowel obstruction or uncontrolled peptic ulcer. 11)History of gastrointestinal perforation within 1 year. 12)Uncontrolled severe complications(DM, hypertension, diarrhea, et al.) 13)History of active double cancer. 14)Massive pleural effusion or ascites that required drainage. 15)Brain metastasis 16)Patients with psycho-neurological disease,central nervous system damage,cerebrovascular disorder 17)Patient receiving surgical procedure or such as skin-open biopsy, trauma surgery, or other more intensive surgeries within 4 weeks or aspiration biopsy within a week. 18)Patient with untreated traumatic bone fracture. 19)Diathesis of bleeding (history of hemoptysis,including cavitation and/or necrosis in lung metastasis confirmed by imaging),coagulopathy. 20) Systemic administration of antiplatelet drug 21)Administration of immunosuppressants associated with organ transplantation 22)Patient who have peripheral nerve disorder 23)Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers. 24)Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
2 期
Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancernresectable metastatic or recurrent colorectal cancerJPRN-UMIN000011552Chubu Clinical Oncology Group (CCOG)25
招募中
2 期
Phase II trial of Bevacizumab with XELOX as an adjuvant treatment after resection of colorectal liver metastasesColorectal liver metastasesJPRN-UMIN000004352Tohoku University Graduate School of Medicine Division of Integrated Surgery and Oncology45
招募中
2 期
Phase II trial of XELOX plus bevacizumab for metastatic colorectal cancer.advanced colorectal cancerJPRN-UMIN000006397agoya Surgical Oncology Group50
已完成
2 期
A randomized phase II study of XELOX plus Bevacizumab versus XELIRI plus Bevacizumab for advanced colorectal cancer with or without mitochondrial transcription factor A (mtTFA) expression.nresectable advanced/recurrent colorectal cancerJPRN-UMIN000005060Fukuoka University Hospital100
已完成
2 期
To evaluate the efficacy of XELOX+Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapycolorectal cancerJPRN-UMIN000003935Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group48